PreMD Continues Appeals For Expanded Skin Cholesterol Test Indication
This article was originally published in The Gray Sheet
Executive Summary
Toronto-based PreMD is exploring a formal scientific dispute against an FDA decision that its Prevu skin cholesterol test is "not substantially equivalent" to other markers of cardiovascular risk